The optimal chemotherapy for stage III non-small cell lung cancer patients

Current Oncology Reports

Volumn 13, Issue 4, 2011, Pages 272-279

  Gadgeel, Shirish M ^a  

^a NONE   (United States)

Author keywords

Concurrent therapy; Stage III NSCLC; Toxicities of concurrent therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; VINBLASTINE; VINDESINE;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; ESOPHAGITIS; ESOPHAGUS FISTULA; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION PNEUMONIA; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TRANSESOPHAGEAL FISTULA; WEIGHT REDUCTION;

EID: 80051664372     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0170-3     Document Type: Review

References (46)

1. JR Jett SE Schild RL Keith KA Kesler 2007 Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 3 Suppl 266S 276S 17873173 10.1378/chest.07-1380
2. JP van Meerbeeck VF Surmont 2009 Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments Lung Cancer 65 3 257 267 19285751 10.1016/j.lungcan.2009.02.007
3. AW Blackstock GJ Lesser J Fletcher-Steede LD Case RW Tucker SM Russo, et al. 2001 Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 51 5 1281 1289 11728688 10.1016/S0360-3016(01)01732-1 1:CAS:528:DC%2BD3MXos1Kmtro%3D (Pubitemid 33116322)
4. SG Divers SA Spencer D Carey EM Busby MD Hyatt F Robert 2005 Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer J Clin Oncol 23 27 6664 6673 16170174 10.1200/JCO.2005.02.519 1:CAS:528:DC%2BD2MXhtFWqsLbL (Pubitemid 46190261)
5. A Auperin PC Le E Rolland WJ Curran K Furuse P Fournel, et al. 2010 Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 13 2181 2190 20351327 10.1200/JCO.2009.26.2543 1:CAS:528:DC%2BC3cXpsFSgsbY%3D This meta-analysis details all the studies that have evaluated concurrent versus sequential chemotherapy
6. RO Dillman J Herndon SL Seagren WL Eaton Jr MR Green 1996 Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 17 1210 1215 8780630 10.1093/jnci/88.17.1210 1:STN:280:DyaK28znsVeguw%3D%3D (Pubitemid 26302034)
7. R Komaki CB Scott WT Sause DH Johnson SG Taylor JS Lee, et al. 1997 Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group Int J Radiat Oncol Biol Phys 39 3 537 544 9336129 10.1016/S0360-3016(97)00365-9 1:CAS:528:DyaK2sXntVGgurc%3D (Pubitemid 27441416)
8. K Furuse M Fukuoka M Kawahara H Nishikawa Y Takada S Kudoh, et al. 1999 Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 9 2692 2699 10561343 1:CAS:528:DyaK1MXmtlWru74%3D (Pubitemid 29415225)
9. Y Segawa K Kiura N Takigawa H Kamei S Harita S Hiraki, et al. 2010 Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007 J Clin Oncol 28 20 3299 3306 20530281 10.1200/JCO.2009.24.7577 1:CAS:528:DC%2BC3cXhtVajurrJ
10. M Machtay C Hsu R Komaki WT Sause RS Swann CJ Langer, et al. 2005 Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience Int J Radiat Oncol Biol Phys 63 3 667 671 15927409 10.1016/j.ijrobp.2005.03.037 (Pubitemid 41400050)
11. P Fournel G Robinet P Thomas PJ Souquet H Lena A Vergnenegre, et al. 2005 Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study J Clin Oncol 23 25 5910 5917 16087956 10.1200/JCO.2005.03.070 1:CAS:528:DC%2BD2MXhtVKgtbzP
12. O'Rourke N, Roque IF, Farre BN, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;(6):CD002140.
13. TE Stinchcombe CB Lee DT Moore MP Rivera J Halle S Limentani, et al. 2008 Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer J Thorac Oncol 3 11 1279 1285 18978563 10.1097/JTO.0b013e31818b1971
14. EE Vokes JE Herndon MJ Kelley MG Cicchetti N Ramnath H Neill, et al. 2007 Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B J Clin Oncol 25 13 1698 1704 17404369 10.1200/JCO.2006.07.3569 1:CAS:528:DC%2BD2sXlvFyktb0%3D (Pubitemid 46797950)
15. CP Belani H Choy P Bonomi C Scott P Travis J Haluschak, et al. 2005 Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol J Clin Oncol 23 25 5883 5891 16087941 10.1200/JCO.2005.55.405 1:CAS:528:DC%2BD2MXhtVKgtbzM
16. DR Gandara K Chansky KS Albain LE Gaspar PN Lara Jr K Kelly, et al. 2006 Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504) Clin Lung Cancer 8 2 116 121 17026812 10.3816/CLC.2006.n.039 1:CAS:528:DC%2BD28XhtFKhsLzF (Pubitemid 44596753)
17. LA Mina MA Neubauer RH Ansari R Govindan LH Einhorn W Fisher, et al. 2008 Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023-Updated results J Clin Oncol (Meeting Abstracts) 26 15-suppl 7519 This is an important randomized study that failed to show benefits of consolidation chemotherapy following completion of concurrent therapy
18. YS Kim EK Choi JS Lee, et al. 2007 Consolidation chemotherapy with monthly paclitaxel and cisplatin (PC) or observation after concurrent chemoradiotherapy for locally advanced Non Small Cell Lung Cancer (NSCLC): Randomized phase II study J Thorac Oncol 2 449s 10.1097/01.JTO.0000283377.55715. 3f abstr PD4-17
19. P Fournel A Vergnenegre G Robinet, et al. 2006 Induction (ICT) or consolidation chemotherapy (CT) with cisplatin and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small-cell lung cancer (NSCLC) patients (pts): Randomized phase II trial GFPC-GLOT-IFCT 02-01 J Clin Oncol 24 376s suppl; abstr 7048
20. FO Ademuyiwa CS Johnson AS White TE Breen J Harvey M Neubauer, et al. 2007 Prognostic factors in stage III non-small-cell lung cancer Clin Lung Cancer 8 8 478 482 17922971 10.3816/CLC.2007.n.031 (Pubitemid 47606356)
21. K Kelly K Chansky LE Gaspar KS Albain J Jett YC Ung, et al. 2008 Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 15 2450 2456 18378568 10.1200/JCO.2007.14.4824 1:CAS:528:DC%2BD1cXnsVKhtbc%3D
22. TY Seiwert PP Connell AM Mauer PC Hoffman CM George L Szeto, et al. 2007 A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer Clin Cancer Res 13 2 Pt 1 515 522 17255273 10.1158/1078-0432.CCR-06-1058 1:CAS:528:DC%2BD2sXoslSlug%3D%3D (Pubitemid 46225357)
23. R Govindan J Bogart X Wang D Liu RA Kratzke EE Vokes 2008 A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-Early evaluation of feasibility and toxicity J Clin Oncol (Meeting Abstracts) 26 15 suppl 7518
24. AM Brade A Bezjak RM MacRae SA Laurie L Wang S Capobianco, et al. 2010 A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 28 15 suppl 7087
25. H Choy LS Schwartzberg SR Dakhil EB Garon JK Choksi R Govindan, et al. 2010 Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update J Clin Oncol (Meeting Abstracts) 28 15 suppl 7082
26. SM Gadgeel JC Ruckdeschel A Wozniak B Patel LK Heilbrun W Chen, et al. 2008 Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients (pts) J Clin Oncol (Meeting Abstracts) 26 15 suppl 7569
27. EE Vokes S Senan JA Treat NA Iscoe 2009 PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology Clin Lung Cancer 10 3 193 198 19443340 10.3816/CLC.2009.n.027 1:CAS:528:DC%2BD1MXmsVChtLc%3D
28. JA Bonner PM Harari J Giralt RB Cohen CU Jones RK Sur, et al. 2010 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 1 21 28 19897418 10.1016/S1470-2045(09)70311-0 1:CAS:528:DC%2BC3cXjslKktA%3D%3D
29. R Pirker JR Pereira A Szczesna J von Pawel M Krzakowski R Ramlau, et al. 2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 9674 1525 31 19410716 10.1016/S0140-6736(09)60569-9 1:CAS:528:DC%2BD1MXltlaqurs%3D
30. GR Blumenschein R Paulus WJ Curran F Robert FV Fossella M Werner-Wasik, et al. 2008 A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial J Clin Oncol (Meeting Abstracts) 26 15 suppl 7516
31. Jensen AD, Munter MW, Bischoff HG, Haselmann R, Haberkorn U, Huber PE, et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 2011, Jan 24.
32. A Jatoi SE Schild N Foster GT Henning KJ Dornfeld PJ Flynn, et al. 2010 A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422) Ann Oncol 21 10 2040 2044 20570832 10.1093/annonc/mdq075 1:STN:280: DC%2BC3cfktFCqsA%3D%3D
33. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528: DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
34. DH Johnson L Fehrenbacher WF Novotny RS Herbst JJ Nemunaitis DM Jablons, et al. 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 11 2184 2191 15169807 10.1200/JCO.2004.11.022 1:CAS:528:DC%2BD2cXpsVWltrg%3D (Pubitemid 41095154)
35. DR Spigel JD Hainsworth DA Yardley E Raefsky J Patton N Peacock, et al. 2010 Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 1 43 48 19901100 10.1200/JCO.2009.24.7353 1:CAS:528:DC%2BC3cXhtF2ku7k%3D Important article detailing the severe toxicities observed in patients treated with bevacizumab with radiation therapy
36. B Goodgame N Veeramachaneni A Patterson R Govindan 2008 Tracheo-esophageal fistula with bevacizumab after mediastinal radiation J Thorac Oncol 3 9 1080 1081 18758321 10.1097/JTO.0b013e3181858eba
37. E Gore A Currey N Choong 2009 Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy J Thorac Oncol 4 12 1590 1591 20009916 10.1097/JTO.0b013e3181c06a6f
38. T Mitsudomi S Morita Y Yatabe S Negoro I Okamoto J Tsurutani, et al. 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2 121 128 20022809 10.1016/S1470-2045(09)70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D
39. TS Mok YL Wu S Thongprasert CH Yang DT Chu N Saijo, et al. 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
40. EL Kwak YJ Bang DR Camidge AT Shaw B Solomon RG Maki, et al. 2010 Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 18 1693 1703 20979469 10.1056/NEJMoa1006448 1:CAS:528:DC%2BC3cXhtlKitL%2FO
41. GD Goss I Lorimer MS Tsao CJ O'Callaghan K Ding GA Masters, et al. 2010 A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 J Clin Oncol (Meeting Abstracts) 28 18 suppl LBA7005
42. KA Olaussen A Dunant P Fouret E Brambilla F Andre V Haddad, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 10 983 991 16957145 10.1056/NEJMoa060570 1:CAS:528:DC%2BD28XpsFKmtLw%3D (Pubitemid 44343542)
43. Z Zheng T Chen X Li E Haura A Sharma G Bepler 2007 DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer N Engl J Med 356 8 800 808 17314339 10.1056/NEJMoa065411 1:CAS:528:DC%2BD2sXhvFKltLs%3D (Pubitemid 46294612)
44. P Ceppi M Volante S Saviozzi I Rapa S Novello A Cambieri, et al. 2006 Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 7 1589 1596 16955506 10.1002/cncr.22208 1:CAS:528:DC%2BD28XhtFersLjK (Pubitemid 44546920)
45. P Ceppi M Papotti G Scagliotti 2010 New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS Adv Med Sci 55 1 22 25 20494871 10.2478/v10039-010-0017-4 1:CAS:528:DC%2BC3cXhtFWgu73P
46. P Zatloukal L Petruzelka M Zemanova L Havel F Janku L Judas, et al. 2004 Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Lung Cancer 46 1 87 98 15364136 10.1016/j.lungcan.2004.03.004 (Pubitemid 39201387)